As of 2025-03-16, the Relative Valuation of Innocan Pharma Corp (INNO.CN) is (0.00) CAD. This relative valuation is based on P/E multiples. With the latest stock price at 0.21 CAD, the upside of Innocan Pharma Corp based on Relative Valuation is -100.6%.
The range of the Relative Valuation is (0.00) - (0.02) CAD.
Note: valuation result may not be accurate due to the company's negative earnings.
| Range | Selected | |
| Trailing P/E multiples | 0.1x - 1.9x | 0.1x |
| Forward P/E multiples | -3.1x - 1.9x | 0.1x |
| Fair Price | (0.00) - (0.02) | (0.00) |
| Upside | -100.5% - -111.8% | -100.6% |
| Date | P/E |
| 2025-03-03 | -15.34 |
| 2025-02-28 | -15.34 |
| 2025-02-27 | -15.34 |
| 2025-02-26 | -15.34 |
| 2025-02-25 | -16.11 |
| 2025-02-24 | -17.64 |
| 2025-02-21 | -16.88 |
| 2025-02-20 | -16.49 |
| 2025-02-19 | -15.73 |
| 2025-02-18 | -13.81 |
| 2025-02-14 | -14.58 |
| 2025-02-13 | -14.58 |
| 2025-02-12 | -14.58 |
| 2025-02-11 | -13.81 |
| 2025-02-10 | -14.19 |
| 2025-02-07 | -14.19 |
| 2025-02-06 | -13.81 |
| 2025-02-05 | -14.19 |
| 2025-02-04 | -14.96 |
| 2025-02-03 | -14.96 |
| 2025-01-31 | -12.27 |
| 2025-01-30 | -13.43 |
| 2025-01-29 | -12.27 |
| 2025-01-27 | -13.04 |
| 2025-01-24 | -13.04 |
| 2025-01-23 | -14.19 |
| 2025-01-22 | -13.81 |
| 2025-01-21 | -13.81 |
| 2025-01-20 | -12.66 |
| 2025-01-17 | -13.81 |
| 2025-01-16 | -13.43 |
| 2025-01-15 | -13.81 |
| 2025-01-14 | -13.43 |
| 2025-01-13 | -13.81 |
| 2025-01-10 | -14.96 |
| 2025-01-09 | -14.19 |
| 2025-01-08 | -14.58 |
| 2025-01-07 | -14.58 |
| 2025-01-06 | -16.11 |
| 2025-01-03 | -15.34 |
| 2025-01-02 | -15.34 |
| 2024-12-31 | -16.11 |
| 2024-12-30 | -16.11 |
| 2024-12-27 | -14.96 |
| 2024-12-24 | -16.11 |
| 2024-12-23 | -14.58 |
| 2024-12-20 | -14.19 |
| 2024-12-19 | -14.96 |
| 2024-12-18 | -14.19 |
| 2024-12-17 | -15.34 |